S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
S&P 500   3,998.09 (+1.18%)
DOW   32,563.80 (+0.99%)
QQQ   308.37 (+0.78%)
AAPL   157.69 (+0.18%)
MSFT   273.72 (+0.55%)
META   201.16 (+1.69%)
GOOGL   101.52 (+0.30%)
AMZN   98.45 (+0.76%)
TSLA   191.27 (+4.38%)
NVDA   261.10 (+0.81%)
NIO   9.25 (+5.71%)
BABA   83.11 (+2.60%)
AMD   98.96 (+2.22%)
T   18.63 (+0.76%)
F   11.57 (+3.49%)
MU   59.18 (+2.67%)
CGC   1.96 (+5.38%)
GE   92.24 (+2.58%)
DIS   95.47 (+1.33%)
AMC   4.35 (+1.87%)
PFE   40.75 (-0.15%)
PYPL   75.20 (+2.72%)
NFLX   302.39 (-0.90%)
NASDAQ:ZIOP

ZIOPHARM Oncology - ZIOP Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$0.82
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ZIOP stock logo

About ZIOPHARM Oncology (NASDAQ:ZIOP) Stock

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Stock News Headlines

Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Cancer Care Market is booming in near Future 2023-2028
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Why This Fund Manager Is Short Ziopharm
ZIOPHARM Oncology (NASDAQ: ZIOP)
CellChorus Announces Scientific Advisory Board
See More Headlines
Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

ZIOP Company Calendar

Last Earnings
11/08/2021
Today
3/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ZIOP
CUSIP
98973P10
Employees
105
Year Founded
2005

Profitability

Net Income
$-79,980,000.00
Pretax Margin
-22,544.97%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.58 per share

Miscellaneous

Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links


Key Executives

  • Kevin S. BoyleKevin S. Boyle
    Chief Executive Officer & Director
  • Timothy M. Cunningham
    Chief Financial Officer
  • Lynn M. Ferrucci
    EVP-Human Resources, Administration & IT
  • Raffaele Baffa
    Chief Medical Officer & Head-Research
  • Eleanor M. de Groot
    General Manager-Cell Therapy & Executive VP













ZIOP Stock - Frequently Asked Questions

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $0.40 million during the quarter. During the same period in the previous year, the company earned ($0.10) earnings per share.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology (NASDAQ:ZIOP) has a market capitalization of $0.00. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

The company employs 105 workers across the globe.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The official website for the company is www.ziopharm.com. The biotechnology company can be reached via phone at (617) 259-1970, via email at dconnolly@ziopharm.com, or via fax at 617-241-2855.

This page (NASDAQ:ZIOP) was last updated on 3/21/2023 by MarketBeat.com Staff